Sanofi India Limited (BOM:500674)
India · Delayed Price · Currency is INR 4,010.25
-47.90 (-1.18%)
At close: Feb 12, 2026
Sanofi India Income Statement
Financials in millions INR. Fiscal year is January - December.
Millions INR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 19,325 | 20,132 | 19,961 | 27,701 | 29,566 | 29,019 | |
Revenue Growth (YoY) | -31.53% | 0.86% | -27.94% | -6.31% | 1.88% | -5.49% |
Cost of Revenue | 9,538 | 9,942 | 9,651 | 12,053 | 13,235 | 12,790 |
Gross Profit | 9,787 | 10,190 | 10,310 | 15,648 | 16,331 | 16,229 |
Selling, General & Admin | 2,140 | 2,598 | 3,050 | 4,414 | 4,836 | 5,164 |
Other Operating Expenses | 2,456 | 2,686 | 2,360 | 4,157 | 3,869 | 3,905 |
Operating Expenses | 4,970 | 5,651 | 5,775 | 8,990 | 9,372 | 9,891 |
Operating Income | 4,817 | 4,539 | 4,535 | 6,658 | 6,959 | 6,338 |
Interest Expense | -15 | -15 | -17 | -17 | -18 | -18 |
Interest & Investment Income | 132 | 132 | 436 | 589 | 631 | 780 |
Currency Exchange Gain (Loss) | 22 | 22 | 16 | 2 | 5 | - |
Other Non Operating Income (Expenses) | 71 | 8 | 145 | 122 | 41 | 117 |
EBT Excluding Unusual Items | 5,027 | 4,686 | 5,115 | 7,354 | 7,618 | 7,217 |
Merger & Restructuring Charges | -193 | -377 | -77 | - | - | - |
Gain (Loss) on Sale of Assets | 5 | 5 | -21 | -2 | 66 | -28 |
Asset Writedown | - | - | - | -29 | - | - |
Other Unusual Items | - | - | 268 | 1,320 | 4,892 | -417 |
Pretax Income | 4,839 | 4,314 | 5,285 | 8,643 | 12,576 | 6,772 |
Income Tax Expense | 1,276 | 1,177 | 1,639 | 2,437 | 3,132 | 1,996 |
Earnings From Continuing Operations | 3,563 | 3,137 | 3,646 | 6,206 | 9,444 | 4,776 |
Earnings From Discontinued Operations | -2 | 996 | 2,383 | - | - | - |
Net Income | 3,561 | 4,133 | 6,029 | 6,206 | 9,444 | 4,776 |
Net Income to Common | 3,561 | 4,133 | 6,029 | 6,206 | 9,444 | 4,776 |
Net Income Growth | -22.54% | -31.45% | -2.85% | -34.29% | 97.74% | 15.31% |
Shares Outstanding (Basic) | 23 | 23 | 23 | 23 | 23 | 23 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 23 | 23 | 23 |
EPS (Basic) | 154.62 | 179.46 | 261.78 | 269.47 | 410.06 | 207.38 |
EPS (Diluted) | 154.62 | 179.46 | 261.78 | 269.47 | 410.06 | 207.38 |
EPS Growth | -22.54% | -31.45% | -2.85% | -34.29% | 97.74% | 15.31% |
Free Cash Flow | - | 4,251 | 1,961 | 3,765 | 5,358 | 5,697 |
Free Cash Flow Per Share | - | 184.58 | 85.15 | 163.48 | 232.65 | 247.37 |
Dividend Per Share | - | 117.000 | 167.000 | 194.000 | 181.000 | 125.000 |
Dividend Growth | - | -29.94% | -13.92% | 7.18% | 44.80% | 17.93% |
Gross Margin | 50.64% | 50.62% | 51.65% | 56.49% | 55.24% | 55.93% |
Operating Margin | 24.93% | 22.55% | 22.72% | 24.04% | 23.54% | 21.84% |
Profit Margin | 18.43% | 20.53% | 30.20% | 22.40% | 31.94% | 16.46% |
Free Cash Flow Margin | - | 21.12% | 9.82% | 13.59% | 18.12% | 19.63% |
EBITDA | 5,177 | 4,852 | 4,847 | 6,984 | 7,537 | 7,091 |
EBITDA Margin | 26.79% | 24.10% | 24.28% | 25.21% | 25.49% | 24.44% |
D&A For EBITDA | 359.5 | 313 | 312 | 326 | 578 | 753 |
EBIT | 4,817 | 4,539 | 4,535 | 6,658 | 6,959 | 6,338 |
EBIT Margin | 24.93% | 22.55% | 22.72% | 24.04% | 23.54% | 21.84% |
Effective Tax Rate | 26.37% | 27.28% | 31.01% | 28.20% | 24.91% | 29.47% |
Revenue as Reported | 19,553 | 20,297 | 20,573 | 28,416 | 30,310 | 29,917 |
Advertising Expenses | - | 179 | 236 | 338 | 461 | 502 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.